IVD devices explained with key types, regulations and selection factors

What are IVD devices?

IVD devices, or in vitro diagnostic devices, are tests, instruments, reagents, systems and related components used to examine specimens taken from the human body. They do not diagnose inside the body. They analyze samples such as blood, urine, saliva, tissue, swabs or other biological materials outside the body, and the results may support screening, diagnosis, disease monitoring, treatment selection, infection control and public health surveillance. In practical terms, IVD devices range from a home pregnancy test to a high-throughput molecular analyzer used in a hospital laboratory. For readers tracking related product categories, more diagnostic technology coverage is available in our Diagnostic Devices section.

The term is broad because the diagnostic process is broad. A single IVD result may depend on sample collection, transport conditions, reagent chemistry, instrument calibration, software interpretation, operator training and quality controls. That is why a serious evaluation of IVD devices should look beyond the test name and consider the full system that produces and reports the result.

Main types of IVD devices

IVD devices can be grouped by technology, clinical use, testing location or regulatory risk. In commercial and clinical practice, the most useful view is often a combination of these categories.

IVD device type	Common examples	Typical use
Clinical chemistry and immunoassay systems	Blood chemistry analyzers, hormone tests, cardiac markers, infectious disease antigen or antibody tests	Routine laboratory testing, emergency care, chronic disease monitoring and screening
Molecular diagnostic devices	PCR systems, nucleic acid amplification tests, sequencing-based assays, respiratory and sexually transmitted infection panels	Pathogen detection, oncology markers, genetic conditions and targeted therapy support
Hematology and coagulation devices	Complete blood count analyzers, coagulation systems, platelet function tests	Blood disorders, surgery preparation, anticoagulation management and general clinical evaluation
Microbiology devices	Culture systems, antimicrobial susceptibility testing, organism identification platforms	Infectious disease diagnosis and antimicrobial stewardship
Point-of-care and rapid tests	Lateral flow tests, glucose meters, cartridge-based analyzers, bedside blood gas systems	Faster decision-making near the patient, often outside a central laboratory
Specimen and workflow systems	Collection tubes, transport media, sample preparation instruments, laboratory automation	Maintaining sample integrity and improving laboratory throughput
Software used with IVD systems	Result interpretation modules, instrument middleware, connectivity and reporting tools	Data handling, signal interpretation, quality control and integration with laboratory systems

The boundaries between these categories are not always clean. A respiratory panel, for example, may be a molecular device, a point-of-care product and a public health surveillance tool at the same time. A cancer biomarker assay may function as both a diagnostic test and a companion diagnostic when it helps identify patients likely to benefit from a specific therapy.

Why IVD devices matter in healthcare decisions

Diagnostics are often less visible than drugs or surgical devices, but their influence is large. The World Health Organization has stated that diagnostic results influence about 70% of healthcare decisions, while diagnostic services receive only a small share of healthcare budgets. That gap helps explain why access, quality and reliability remain recurring policy themes in diagnostics.

For clinicians, a dependable IVD result can shorten time to treatment, reduce unnecessary prescribing, identify patients at risk and guide follow-up. For hospitals and laboratories, the value of a device also depends on throughput, uptime, reagent availability, staff training needs and compatibility with existing workflows. For public health agencies, IVD devices support outbreak detection, disease surveillance and screening programs.

More testing, however, does not automatically mean better care. Poorly selected tests can create false reassurance, unnecessary follow-up, inappropriate treatment or data that clinicians cannot use. The value of an IVD device depends on whether the right test is used for the right population, with validated performance, clear interpretation and appropriate quality management.

Regulatory factors shaping IVD devices in 2026

As of October 2026, the regulatory environment for IVD devices is shaped by two parallel pressures: stronger expectations for evidence and quality, and continued efforts to avoid shortages or disruption during regulatory transitions. Three source groups are especially useful for understanding this landscape: the U.S. Food and Drug Administration, the European Commission and EUR-Lex for EU rules, and the World Health Organization for global access and procurement context.

United States FDA classification and CLIA context

In the United States, FDA materials describe IVD products as devices used to collect, prepare and examine specimens taken from the human body for diagnosis or health assessment. FDA classifies medical devices, including IVD products, into Class I, Class II or Class III according to the regulatory controls needed to provide reasonable assurance of safety and effectiveness. That classification helps determine whether a product may need a pathway such as 510(k), De Novo classification or premarket approval.

Laboratory testing in the United States is also shaped by CLIA, the Clinical Laboratory Improvement Amendments. CLIA focuses on laboratory quality and categorizes tests by complexity, including waived, moderate complexity and high complexity testing. This matters because an IVD device may be authorized or cleared for a certain use, while the testing environment, personnel requirements and laboratory quality system still affect real-world implementation.

The laboratory developed test issue changed after 2025

Laboratory developed tests, often called LDTs, have been one of the most debated areas in U.S. diagnostics policy. FDA issued a final rule on May 6, 2024 that sought to amend the definition of in vitro diagnostic products and phase out the agency’s general enforcement discretion approach for many LDTs. On March 31, 2025, a federal district court vacated that rule. FDA then issued a final rule on September 19, 2025 reverting the regulation text to its pre-2024 wording.

The practical takeaway is important: the 2024 LDT phaseout should not be treated as an active FDA implementation schedule in 2026. At the same time, this does not remove regulatory obligations for commercial IVD manufacturers or eliminate CLIA responsibilities for laboratories. It simply means the specific vacated LDT rule is not the current governing framework.

EU IVDR transition deadlines remain central

In the European Union, the In Vitro Diagnostic Medical Devices Regulation, known as IVDR or Regulation (EU) 2017/746, replaced the older IVDD framework. IVDR introduced a risk-based classification system from Class A to Class D, with higher classes generally requiring greater notified body involvement and evidence. New devices and legacy Class A non-sterile devices have been under IVDR requirements since May 2022.

Because the transition from IVDD to IVDR created capacity and availability concerns, Regulation (EU) 2024/1860 extended certain transition periods for eligible legacy devices. The key end dates are December 31, 2027 for Class D devices, December 31, 2028 for Class C devices, and December 31, 2029 for Class B and sterile Class A devices, subject to conditions. Those conditions include continued compliance with the previous framework, no significant design or intended-purpose changes, no unacceptable risk, an IVDR-compliant quality management system by May 26, 2025, and timely notified body applications for devices requiring conformity assessment.

For manufacturers and distributors, the extension is not a reason to delay technical documentation. It is a conditional bridge. Companies that miss application or quality-system milestones may lose access to the transition period even if the headline deadline appears later.

WHO’s role in access and procurement

The World Health Organization does not replace national regulators, but its work is influential for access and procurement. WHO promotes the Essential Diagnostics List and maintains prequalification activities for selected IVD products. WHO describes prequalified IVD products as products assessed and found acceptable in principle for procurement by United Nations agencies, while also noting that inclusion is not the same as national approval and that the list is not exhaustive. See also: clinical equipment.

This distinction matters for global health buyers. WHO prequalification can support procurement confidence, especially in infectious disease programs, but local authorization, intended use, supply terms, training and post-market obligations still need to be checked in each country or region.

How to evaluate IVD devices before selection

Comparing IVD devices only by price per test is risky. The purchase price of an analyzer or kit may be a small part of the total cost once quality controls, calibrators, service, waste handling, staff time, repeat testing and downtime are included. A structured evaluation should cover the following areas.

• Intended use and claims: Confirm the disease area, target analyte, specimen type, user setting and patient population. A test validated for one sample type or care setting should not be assumed to work equally in another.
• Analytical performance: Review precision, limit of detection, measuring range, interference, cross-reactivity, stability, carryover and reproducibility. For qualitative tests, sensitivity and specificity must be understood in the relevant population.
• Clinical performance: Ask whether results meaningfully support diagnosis, screening, prognosis, monitoring or therapy selection. Analytical accuracy alone is not enough if the clinical interpretation is weak.
• Workflow fit: Consider sample preparation, hands-on time, turnaround time, throughput, maintenance and staff training. A technically strong system can fail operationally if it does not fit the laboratory’s workload.
• Quality controls and traceability: Evaluate built-in controls, external controls, calibrator availability, lot-to-lot consistency and documentation for audits.
• Connectivity and cybersecurity: For connected systems, check laboratory information system integration, data export, access controls, update policies and responsibility for software changes.
• Regulatory and market status: Verify the authorization, clearance, CE marking, registration or local approval that applies to the target jurisdiction. Do not rely on approvals from one market as proof of availability in another.
• Supply continuity: Review reagent shelf life, cold-chain needs, service coverage, spare parts, alternative suppliers and change-notification policies.

For procurement teams, the strongest approach is to map the device to a specific clinical decision. If the device does not improve a decision, shorten a pathway, expand access or reduce uncertainty, its technical specifications alone may not justify adoption.

Key trends to watch

Several trends are shaping the next stage of IVD devices. First, molecular and multiplex testing is moving beyond specialized laboratories into more decentralized settings. That shift can improve speed, but it also raises questions about operator training, contamination control, result interpretation and cost.

Second, point-of-care testing continues to expand. The benefit is faster action near the patient; the risk is uneven quality if governance is weak. Hospitals adopting point-of-care IVD devices need clear responsibility for training, maintenance, quality control and result connectivity.

Third, software is becoming more important. Instruments increasingly rely on algorithms, middleware and automated interpretation. This makes validation, version control, cybersecurity and change management part of diagnostic quality, not just information technology support.

Fourth, regulatory planning has become a market-access issue. EU IVDR deadlines and the post-2025 U.S. LDT situation show that manufacturers, laboratories and buyers cannot treat regulation as a final paperwork step. Evidence strategy, quality systems and lifecycle documentation need to be built into product planning from the beginning.

Frequently asked questions

Are IVD devices the same as laboratory equipment?

Not exactly. Some IVD devices are laboratory instruments, but the category also includes reagents, test kits, controls, specimen collection components, software and complete testing systems. The defining feature is the intended diagnostic use with specimens taken from the human body.

Are all IVD devices used in hospitals?

No. Many are used in central laboratories and hospitals, but others are used in clinics, public health programs, blood banks, physician offices, pharmacies, homes and field settings. The intended user and setting are important parts of the device’s validation and regulatory status.

What is the difference between an IVD device and an LDT?

An IVD device is a broad product category that can include commercial test kits, instruments and systems. An LDT generally refers to a test designed, manufactured and used within a laboratory. The U.S. regulatory position on LDTs changed after the 2024 FDA final rule was vacated in 2025, so older summaries of that rule should be read cautiously.

Do EU IVDR transition deadlines apply to every IVD device?

No. The extended IVDR transition periods apply only to eligible legacy devices that meet specific conditions. New devices and legacy Class A non-sterile devices generally needed to comply with IVDR from May 2022. Manufacturers should verify class, certificate status, declaration history, quality-system timing and notified body application requirements.

What should buyers check first when comparing IVD devices?

Start with intended use, regulatory status in the target market, specimen type, performance evidence and workflow fit. Price matters, but a low-cost test can become expensive if it increases repeat testing, delays decisions, requires unsupported workflows or lacks reliable supply.